Presently,somatic Cell Gene Therapy for ADA-SCID Presents Challenges

Question

Presently,somatic cell gene therapy for ADA-SCID presents challenges.What are those challenges?
A) The therapy is too expensive
B) The therapy is transient an the gene promoters are silenced by the host quickly
C) The functional gene copy is lost during introduction
D) The lifespan of red blood cells is short
E) None of these

Accepted Answer

Somatic cell gene therapy for ADA-SCID presents challenges in that the therapy is transient and the gene promoters are silenced by the host quickly. These challenges limit the effectiveness and duration of the therapy. The other options, such as the cost of the therapy and the lifespan of red blood cells, may also present challenges, but they are not specific to ADA-SCID gene therapy.